739 related articles for article (PubMed ID: 26791163)
1. A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis.
Rauch A; Caron C; Vincent F; Jeanpierre E; Ternisien C; Boisseau P; Zawadzki C; Fressinaud E; Borel-Derlon A; Hermoire S; Paris C; Lavenu-Bombled C; Veyradier A; Ung A; Vincentelli A; van Belle E; Lenting PJ; Goudemand J; Susen S
Thromb Haemost; 2016 May; 115(5):950-9. PubMed ID: 26791163
[TBL] [Abstract][Full Text] [Related]
2. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.
Flood VH; Gill JC; Morateck PA; Christopherson PA; Friedman KD; Haberichter SL; Hoffmann RG; Montgomery RR
Blood; 2011 Feb; 117(6):e67-74. PubMed ID: 21148813
[TBL] [Abstract][Full Text] [Related]
3. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
4. Differences in von Willebrand factor function in type 2A von Willebrand disease and left ventricular assist device-induced acquired von Willebrand syndrome.
Deconinck S; Tersteeg C; Bailleul E; Delrue L; Vandeputte N; Pareyn I; Itzhar-Baikian N; Deckmyn H; De Meyer SF; Vanderheyden M; Vanhoorelbeke K
Res Pract Thromb Haemost; 2018 Oct; 2(4):762-766. PubMed ID: 30397685
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome.
Stufano F; Boscarino M; Bucciarelli P; Baronciani L; Maino A; Cozzi G; Peyvandi F
Semin Thromb Hemost; 2019 Feb; 45(1):36-42. PubMed ID: 29913537
[TBL] [Abstract][Full Text] [Related]
6. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
7. Comparison of an automated chemiluminescent assay to a manual ELISA assay for determination of von Willebrand Factor collagen binding activity on VWD plasma patients previously diagnosed through molecular analysis of VWF.
Jousselme E; Jourdy Y; Rugeri L; Négrier C; Nougier C
Int J Lab Hematol; 2018 Feb; 40(1):77-83. PubMed ID: 28980759
[TBL] [Abstract][Full Text] [Related]
8. Successful Perioperative Management of Orthotopic Cardiac Transplantation in a Pediatric Patient With Concurrent Congenital von Willebrand Disease and Acquired von Willebrand Syndrome Using Recombinant von Willebrand Factor.
Batsuli G; Zimowski KL; Carroll R; White MH; Woods GM; Meeks SL; Sidonio RF
J Cardiothorac Vasc Anesth; 2022 Mar; 36(3):724-727. PubMed ID: 33618961
[TBL] [Abstract][Full Text] [Related]
9. Establishing a method for in vitro investigation of mechanical parameters causing acquired von Willebrand syndrome in ventricular assist devices.
Egger C; Maas J; Hufen T; Schmitz-Rode T; Steinseifer U
Artif Organs; 2013 Sep; 37(9):833-9. PubMed ID: 23834027
[TBL] [Abstract][Full Text] [Related]
10. Detection of acquired von Willebrand syndrome after ventricular assist device by total thrombus-formation analysis system.
Takashio S; Kaikita K; Nishi M; Morioka M; Higo T; Shiose A; Doman T; Horiuchi H; Fukui T; Tsujita K
ESC Heart Fail; 2020 Oct; 7(5):3235-3239. PubMed ID: 32700467
[TBL] [Abstract][Full Text] [Related]
11. Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.
Veyradier A; Caron C; Ternisien C; Wolf M; Trossaert M; Fressinaud E; Goudemand J
Haemophilia; 2011 Nov; 17(6):944-51. PubMed ID: 21371195
[TBL] [Abstract][Full Text] [Related]
12. Comparison between von Willebrand factor (VWF) and VWF antigen II in normal individuals and patients with von Willebrand disease.
de Romeuf C; Mazurier C
Thromb Haemost; 1998 Jul; 80(1):37-41. PubMed ID: 9684782
[TBL] [Abstract][Full Text] [Related]
13. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
Michiels JJ; van Vliet HH
Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
[TBL] [Abstract][Full Text] [Related]
14. Clinical and laboratory phenotype variability in type 2M von Willebrand disease.
Doruelo AL; Haberichter SL; Christopherson PA; Boggio LN; Gupta S; Lentz SR; Shapiro AD; Montgomery RR; Flood VH
J Thromb Haemost; 2017 Aug; 15(8):1559-1566. PubMed ID: 28544236
[TBL] [Abstract][Full Text] [Related]
15. Acquired Von Willebrand syndrome is an early-onset problem in ventricular assist device patients.
Heilmann C; Geisen U; Beyersdorf F; Nakamura L; Trummer G; Berchtold-Herz M; Schlensak C; Zieger B
Eur J Cardiothorac Surg; 2011 Dec; 40(6):1328-33; discussion 1233. PubMed ID: 21515067
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of von Willebrand factor profiles after implantation of left ventricular assist device and total artificial heart.
Reich HJ; Morgan J; Arabia F; Czer L; Moriguchi J; Ramzy D; Esmailian F; Lam L; Dunhill J; Volod O
J Thromb Haemost; 2017 Aug; 15(8):1620-1624. PubMed ID: 28586149
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.
Geisen U; Zieger B; Nakamura L; Weis A; Heinz J; Michiels JJ; Heilmann C
Thromb Res; 2014 Aug; 134(2):246-50. PubMed ID: 24891215
[TBL] [Abstract][Full Text] [Related]
18. von Willebrand disease type 2A phenotypes IIC, IID and IIE: A day in the life of shear-stressed mutant von Willebrand factor.
Brehm MA; Huck V; Aponte-Santamaría C; Obser T; Grässle S; Oyen F; Budde U; Schneppenheim S; Baldauf C; Gräter F; Schneider SW; Schneppenheim R
Thromb Haemost; 2014 Jul; 112(1):96-108. PubMed ID: 24598842
[TBL] [Abstract][Full Text] [Related]
19. A Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease.
Vanhoorelbeke K; Cauwenberghs N; Vandecasteele G; Vauterin S; Deckmyn H
Semin Thromb Hemost; 2002 Apr; 28(2):161-6. PubMed ID: 11992239
[TBL] [Abstract][Full Text] [Related]
20. Technological advances in diagnostic testing for von Willebrand disease: new approaches and challenges.
Hayward CP; Moffat KA; Graf L
Int J Lab Hematol; 2014 Jun; 36(3):334-40. PubMed ID: 24750680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]